• Disrupter insulin with potential to be the first ultra-concentrated and ultra-rapid acting insulin available for patients
  • The insulin candidate aims to significantly improve glucose control and reduce injection volume and potentially enable fewer injections per day for people with Type 2 diabetes who have high insulin needs
  • Ultra-concentrated, ultra-rapid acting insulin such as AT278 is critical to development of next generation miniaturised insulin delivery devices
  • Trial expected to complete in Q4 2023

Arecor Therapeutics plc, Calculus portfolio company, today announces that the first patient has been dosed in its Phase I clinical trial investigating AT278, an ultra-rapid acting, ultra-concentrated insulin candidate, in Type 2 diabetic patients, the primary target population.

The trial will look to build on the success of the trial in Type 1 diabetics and to prove how the candidate insulin can revolutionise the treatment of Type 2 Diabetes, especially within the cohort who have high insulin requirements.

Sarah Howell, Chief Executive Officer at Arecor, said: “Having already demonstrated AT278’s very promising profile in Type 1 diabetes patients, we look forward to furthering our understanding of its potential impact in Type 2 diabetes patients, the primary target market for this potential insulin treatment.

“The number of people living with Type 2 diabetes is increasing year-on-year and driven by the obesity epidemic, many are becoming insulin resistant, requiring large volumes of insulin and multiple injections to manage their condition, which is a heavy daily burden. With no concentrated (>200 U/mL) rapid acting insulin products on the market, AT278 could be the first such product available to patients, enabling effective blood glucose management alongside the convenience and compliance benefits of high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting, concentrated insulin is a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices.”